Ipsen, Santhera Agree On Fipamezole License Outside North America, Japan
03 9월 2010 - 3:08PM
Dow Jones News
French drug firm Ipsen (IPN.FR) said Friday that it has reached
a license agreement with Swiss specialty pharmaceutical company
Santhera Pharmaceuticals (SANN.EB) for the development and sale of
fipamezole outside North America and Japan.
The drug is under investigation for the treatment of dyskinesia
in Parkinson's disease, with a first Phase III study scheduled for
2011, Ipsen said in a statement.
Under the agreement, the French biopharmaceutical group has the
rights to fipamezole outside the U.S., Canada and Japan for an
upfront payment of EUR13 million and additional payments of up to
EUR128 million contingent to future development, regulatory and
sales milestones. In addition, Santhera is entitled to royalty
payments on Ipsen's future sales.
-By Angeline Benoit, Dow Jones Newswires; +33 1 4017 1740;
angeline.benoit@dowjones.com
Ipsen (PK) (USOTC:IPSEY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Ipsen (PK) (USOTC:IPSEY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Ipsen SA (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Ipsen S.A. ADS News Articles